There are several research clinics and institutes that are seeking participants for their studies and clinical trials right now! Please see below to find a clinical trial that appropriate for you. Also, if you have specific questions about clinical trials that might be appropriate for you, please reach out to our PNW Chapter Clinical Trial Education Volunteers (CTEV) Laura Tremblay (LDTremblay71@gmail.com), Jude Restis (JRestis@yahoo.com), and/or Mark Smith (Mark@earthdr.com).
BENAROYA RESEARCH INSTITUTE – SEATTLE
If interested in any of these studies or have any questions, please contact: diabetes@benaroyaresearch.org, 1-800-888-4187.
βETA PRESERVE Study
This study is looking at how an investigational study drug, called teplizumab, might possibly help protect insulin producing cells by affecting the immune cells that attack them.
You may be eligible for this study if you:
- Are 1 – 25 years old
- Have been diagnosed with T1D within the past month
This study is also enrolling at Rocky Mountain Clinical Research – Idaho Falls (below).
FABULINUS Study
This study is testing an investigational drug called frexalimab in people with newly-diagnosed T1D. Frexalimab is thought to work by blocking pathways of immune cell activation and function.
You can help researchers understand:
- If frexalimab can preserve the body’s own insulin production.
- If frexalimab can help the body control blood glucose levels.
- If frexalimab can decrease the dose of insulin.
- How safe frexalimab is.
You may be eligible for this study if you are:
- Age 12-21 years old
- Newly-diagnosed with T1D in the past 3 months
This study is also enrolling at Rocky Mountain Clinical Research – Idaho Falls (below).
SAFEGUARD Study
The SAFEGUARD study will evaluate the safety and efficacy of an investigational medicine called SAB-142 in delaying disease progression in people newly diagnosed with T1D.
Ages 15-40 will be enrolled first, followed by 5 to 40-year-olds later in the study.
You/your child may qualify to participate in the SAFEGUARD clinical study if the following criteria are met:
- Aged between 5 to 40 years, inclusively
- Newly diagnosed with T1D (enrolled in the study within 100 days of diagnosis)
Benaroya Research Institute Autoimmune Registry
The Benaroya Research Institute Autoimmune Registry (BRIAR) is a voluntary registry for individuals interested in participating in autoimmune disease research. Whether you live with an autoimmune condition, have a family member who does, or would like to be a healthy control volunteer, joining BRIAR helps advance scientific understanding and supports the development of future treatments.
You are eligible to join BRIAR if you have any of the following:
- a personal history of one or more autoimmune/immune-mediated condition(s)
- a healthy immune system, without any autoimmune/immune-mediated conditions
- a family history of one or more autoimmune/immune-mediated condition(s)
Parents or legal guardians may register on behalf of a child under age 18.
By enrolling, you will provide basic health information that helps us match you to current and future studies, and you will receive periodic research updates from Benaroya Research Institute (BRI). All the information you provide will be kept confidential and participation in future studies is always voluntary.
ROCKY MOUNTAIN CLINICAL RESEARCH – IDAHO FALLS
βETA PRESERVE Study
This study is looking at how an investigational study drug, called teplizumab, might possibly help protect insulin producing cells by affecting the immune cells that attack them.
You may be eligible for this study if you:
- Are 1 – 25 years old
- Have been diagnosed with T1D within the past month
If interested in βETA PRESERVE, please contact rockymountainclinicalresearch@idahomed.com, 208-522-6005
This study is also enrolling at Benaroya Research Institute – Seattle (above).
FABULINUS
Rocky Mountain Clinical Research Center in Idaho Falls is another site for the FABULINUS trial. This trial is testing how well an investigational study drug preserves pancreatic beta cell function in people recently diagnosed with type 1 diabetes. Study participants will continue their insulin therapy and will have their glucose monitored throughout the study in accordance with the study protocol. Researchers hope to see if the investigational study drug can help people with T1D better control their glucose levels.
Participants will receive at no cost: study product or placebo, a continuous glucose monitor, an electronic diary, a blood glucose meter, study visits and study-specific procedures.
The study length is 2.5 years.
You may be eligible for this trial is you are:
- Age 12-21 years old
- Newly diagnosed with T1D and on insulin therapy for 90 days or less
If interested in FABULINUS, please contact rockymountainclinicalresearch@idahomed.com, 208-522-6005
ONWARDS 11 Study
This study is comparing the safety and efficacy of once weekly icodec long-acting insulin versus once daily glargine (Lantus) long-acting insulin, both in combination with fast-acting insulin aspart (Novolog).
You may be eligible for this study if you:
- Are 18 years or older
- Have been diagnosed with T1D for at least one year
- Have an A1C 7.0%-10.0%
- Have been using multiple daily injections (MDIs) for at least 6 months before screening
If interested in ONWARDS 11, please contact rockymountainclinicalresearch@idahomed.com, 208-522-6005
This study is also enrolling at Rainier Clinical Research Center – Renton (below).
OHSU – PORTLAND
SUGARNSALT
This trial is determining if an investigational oral medication called Sotagliflozin (SOTA) can help slow kidney function decline in patients with type 1 diabetes. SOTA is a drug in the family of medications called SGLT1 and SGLT2 (sodium/glucose transport) inhibitors and is currently approved by the FDA to reduce the risk of being admitted to the hospital due to heart failure in persons with type 2 diabetes and other conditions. Some studies have shown that drugs like SOTA may also slow the progression of kidney disease in people with and without diabetes.
You may be eligible to participate if you are:
- Diagnosed with type 1 diabetes for at least 8 years and continuously treated with insulin
- Between the ages of 18 and 75 years
- Have been told by your doctor that you have diabetic kidney disease or protein in your
urine
If you are interested in participating in this trial, please contact OHSU study staff (Aly Carlson or Krista Metas) by phone or email:
Aly Carlson: 971-610-3005
Krista Metas: 971-484-5758
Email: sugarnsalt@ohsu.edu
Context AWARE Study
An artificial pancreas (AP) is a control system for automatic insulin delivery. The investigators have implemented a high blood sugar detection and dosing algorithm for use within an AP control system. If a high blood sugar pattern is detected, correction insulin will be calculated and delivered. The investigators will test how well the new algorithm manages glucose compared to the AP control system without high blood sugar detection and dosing. This type of algorithm may improve glucose control for high risk patient populations. Participants will wear an Omnipod paired with a Dexcom G6, as well as a fitness watch to track activity data.
You may be eligible for this study if you :
- Are 18 years old or older
- Have been diagnosed with T1D for at least one year
- Have an HbA1c or GMI ≥ 7.0% at screening
- Are physically willing and able to perform 30 min of exercise (as determined by the investigator after reviewing the participant’s activity level)
- Have been using an FDA-approved hybrid closed loop system for ≥ 3 months
- Live with another person aged 18 or older who will sleep in the house at night and that can attend the training on using the system
- Live within 40 miles of OHSU
If you are interested in participating in this trial, please contact OHSU study staff (Samrita Thapa or Matthew Howard) by phone or email:
Samrita Thapa: 503-494-8421
Matthew Howard: 503-418-2209
Email: oregonapc@ohsu.edu
Development and Evaluation of App-Based Certified Diabetes Education (AB-CDE) Study
This 38-week clinical research study aims to evaluate how advanced technology, and personalized support can help people with type 1 diabetes improve their glucose control.
Participants will use several innovative tools, including the Dexcom G6 continuous glucose monitor (CGM), an insulin dose capture system (Tempo pens and Tempo button), and the DailyDose app, which provides tailored insulin dosing recommendations. Each participant will also receive an iPhone and Apple Watch to collect data on sleep and physical activity. After a two-week run-in period, participants will be randomized into either a control group of an intervention group.
Those in the intervention group will receive training to use the full DailyDose system, which provides personalized insulin dosing recommendations based on glucose, insulin, meal, and exercise data phase whereas control group will continue standard data logging which involves use of the Dexcom G6 CGM, the insulin dose capture system (Tempo pens and Tempo button), and the Data-logging Mode of DailyDose for the entire study.
The AB-CDE Study aims to demonstrate how digital tools and behavioral support can empower individuals with type 1 diabetes to achieve better long-term health outcomes.
You may be eligible for this study if you:
- Are 18 years old or older
- Have been diagnosed with T1D for at least one year
- Have an HbA1c 7.5-11%
- Use multiple insulin injection therapy
If you are interested in participating in this trial, please contact OHSU study staff (Samrita Thapa or Matthew Howard) by phone or email:
Samrita Thapa: 503-494-8421
Matthew Howard: 503-418-2209
Email: oregonapc@ohsu.edu
UNIVERSITY OF WASHINGTON – SEATTLE
CNP-103
This study is looking at the safety, tolerability, pharmacodynamics, and efficacy of CNP-103. CNP-103 is an investigational, first-in-class, antigen-specific therapy. CNP-103 is designed to preserve insulin production by targeting the autoimmune attack on beta cells, which may improve blood sugar control and long-term outcomes.
You may be eligible for this study if you:
- Are 18-35 years old
- Were diagnosed with T1D within 180 days (6 months)
If interested, please contact: Dori Khakpour, dorik@uw.edu
CATT1 Study
The CATT1 Study will look at whether the study drug, cadisegliatin (also called TTP339), can reduce the frequency of low blood sugar (hypoglycemia) in adults with type 1 diabetes. The study drug is a tablet taken by mouth. It is designed to stimulate the liver and improve the liver’s ability to store sugar from food, which may reduce episodes of high or low blood sugar.
You may be eligible for this study if you:
- Are at least 18 years old
- Need help managing your low blood sugar from type 1 diabetes
If interested, please contact: Darinka Gil, dgm91@uw.edu
REMODEL T1D
REMODEL T1D is looking at the potential benefits of the GLP-1 agonist, Semaglutide, on kidney function in people with abnormal kidney function due to T1D. A secondary objective is to study the glycemic effects of Semaglutide in people with T1D. The study will last 26 weeks, including a gradual titration of study medications to maximum target dose over 12 weeks, followed by evaluation of the effect of Semaglutide on the kidney. Evaluation will include kidney MRI, urine testing and blood testing.
You may be eligible for this study if you:
- Are 18 years of age or older
- Have been diagnosed with T1D for at least 5 years
- Have abnormal kidney function due to T1D
- Are on stable doses of medications for blood pressure and cholesterol
If interested, please contact: Darinka Gil, dgm91@uw.edu
T1-DISCO – Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
The purpose of this study is to learn more about the effects of an investigational drug called semaglutide (Ozempic™), as a safe and effective means of improving cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. Semaglutide is considered investigational because it is an FDA-approved drug being used off-label. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. UW will perform a randomized study to assess the effects of 8 months of once weekly subcutaneous semaglutide vs. once weekly placebo injections. If participants join the study, they will have one screening visit, one 8-month treatment phase, two long study visits, two MRI visits, four interim visits, and one follow-up visit over approximately 9 months. They will be asked to take the study medication or a placebo, for a period of 8 months.
If interested, please contact: Bri Hihara, bhihara@uw.edu
SUGARNSALT
This study involves taking a tablet of sotagliflozin (SOTA) or an identical tablet without any active drug (200 mg) every day for about 3 years and 4 months. The study involves 19 study visits including one that can be done over the phone. SOTA is currently approved to reduce the risk of being admitted to the hospital due to heart failure, or dying of cardiovascular disease, in persons with type 2 diabetes and other conditions. SOTA is not currently approved to improve glycemic control in patients with type 1 diabetes. SOTA is also not currently approved to slow progression of kidney disease in diabetes. However, the FDA has reviewed this study and has granted the investigators permission to use SOTA to investigate whether it can have a beneficial effect on kidney function in type 1 diabetes.
Participants will receive $50 for each study visit, except visit 5, which is a short visit done at the same time as visit 4 or as a brief telephone call. If interested, please contact: Paul Ly, lypaul@uw.edu
INHALE AID Ex Study
INHALE AID Ex is an inhale insulin study for those with T1D on Tandem t:slim X2 insulin pump with control-IQ. The study wants to see if inhale insulin given for a meal is safer and better to use than a bolus of insulin through the pump when exercise follows a meal. About 30 people will be in the study at 3 sites in the U.S.
You may be eligible for this study if you:
- Have Type 1 Diabetes and are between 18 and 60 years of age
- Use a Tandem insulin pump with Control IQ
- Are physically active, currently doing exercise sessions
- Can complete a 45-minutes brisk walk on a treadmill
- Would like to help us determine if taking inhaled insulin at mealtime causes less low blood sugar during exercise compared to Novolog or Humalog
Can you attend 4 visits in clinic? Compensation for your time and travel provided.
If interested, please contact: Jessica Baran, jbaran@uw.edu
SEATTLE CHILDREN’S HOSPITAL
MANATEE T1D
Metformin and Automated Insulin Delivery system effects on renal vascular resistance, insulin sensitivity, and cardiometabolic function in youth with type 1 diabetes.
This study is a randomized, double-blind, placebo-controlled trial being conducted at Seattle Children’s Hospital. The purpose of this study is to learn about the health effects on the kidney, blood vessels, and insulin sensitivity of combining two treatments – an automated insulin delivery system and metformin – for people ages 12-25 years old who have had type 1 diabetes for at least 6 months. Participants can be using either an insulin pump or multiple daily injections (MDIs). The use of metformin in this study is experimental. Study participants will be randomized to receive metformin or a placebo for the study period of 4 months.
If interested, please contact: Kevin Bocek, Kevin.Bocek@seattlechildrens.org, 206-643-5599 or Amelia Johnson, amelia.johnson3@seattlechildrens.org.
WAVE T1D
This study is being done in people with newly diagnosed Type 1 Diabetes (T1D) to see if using a treatment called Anti-thymocyte Globulin (ATG), followed by either Adalimumab or Verapamil, can help people keep making insulin for a longer time which may also help control blood glucose. Participants will be in the study for up to 3 years, including approximately 12 office visits and at least 6 scheduled phone contacts.
You may be eligible for this study if you:
- Have been recently diagnosed with T1D and can start the treatment phase within 6 months of your diagnosis.
- Are between 9 and 20 years old
- Weigh more than 66lbs
- Can read and understand English or Spanish
- Are up-to-date on recommended vaccines for your age and willing to avoid certain live vaccines during the study
- Use only insulin to control blood sugar (no other glucose-lowering medicine)
If interested, please contact: Kevin Bocek, Kevin.Bocek@seattlechildrens.org, 206-643-5599 or Amelia Johnson, amelia.johnson3@seattlechildrens.org.
GATEWAY
Medtronic is launching a new study of its next-generation closed-loop system, pairing the NMX8 screenless insulin pump with the DS5 disposable CGM. The system uses the investigational NMX algorithm, designed to automate more of the daily diabetes care, including basal insulin, correction dose, and even meal boluses. Participants with Type 1 or Type 2 diabetes who use insulin will be randomized into one of three meal-handling approaches, ranging from no meal announcements to full flexibility. A study smartphone is provided, and eligible participants will use one of the several rapid-acting insulins during the trial.
You may be eligible for this study if you:
- Are 7 years old or older
- Have been living with T1D for at least 6 months
If interested, please contact: Barbara Maslaney, barbara.maslaney@seattlechildrens.org, 206-884-8540.
This study is also enrolling at Rainier Clinical Research Center – Renton (below).
RAINIER CLINICAL RESEARCH CENTER – RENTON
If you are interested in one or more of the trials below or have any questions, please contact the Site Coordinator at RCRC at recruitment@rainier-research.com or call 888-478-8343.
OPT-200
This study is looking to explore the effects of subcutaneous study medication on sustaining or increasing C-peptide production in those diagnosed with T1D. The study medication blocks a major mechanism of the immune attack on beta cells. C-peptide levels are a by-product of insulin production. When insulin production rises, C-peptide levels increase. Parts B and C of the study are currently enrolling. Participants may receive study drug or placebo with a total participation of 48 weeks.
You may be eligible for the Part B enrollment group if you:
- Are 18-50 years old
- Have been diagnosed in the last 1-10 years
You may be eligible for the Part C enrollment group if you:
- Are 18-50 years old
- Have been diagnosed in the last 12 months
GATEWAY
Medtronic is launching a new study of its next-generation closed-loop system, pairing the NMX8 screenless insulin pump with the DS5 disposable CGM. The system uses the investigational NMX algorithm, designed to automate more of the daily diabetes care, including basal insulin, correction doses, and even meal boluses. Participants with Type 1 or Type 2 diabetes who use insulin will be randomized into one of three meal-handling approaches, ranging from no meal announcements to full flexibility. A study smartphone is provided, and eligible participants will use one of the several rapid-acting insulins during the trial.
You may be eligible for this study if you:
- Are 18-85 years old
- Have been living with T1D for at least 6 months
This study is also enrolling at Seattle Children’s (above).
Dexcom G7
This home wear study is evaluating a modified version of the Dexcom G7 continuous glucose monitoring (CGM) system. While the Dexcom G7 is FDA approved, the version used in this study includes investigational updates and is being tested for research purposes only.
Participants will wear the study device for up to 15.5 days. The sensor connects to a smartphone app, allowing glucose information to be viewed throughout the wear period.
To help compare CGM readings with standard measurements, participants will be asked to complete up to seven fingerstick blood sugar checks per day during home wear. A blood glucose meter and supplies will be provided.
ONWARDS 11 Study
This study is comparing the safety and efficacy of once weekly icodec long-acting insulin versus once daily glargine (Lantus) long-acting insulin, both in combination with fast-acting insulin aspart (Novolog).
You may be eligible for this study if you:
- Are 18 years old or older
- Have been diagnosed with T1D for at least one year
- Have an A1C of 7.0-10.0%
- Have been using multiple daily insulin injections (MDIs) for at least 6 months before screening
This study is also enrolling at Rocky Mountain Clinical Research – Idaho Falls (above).
FREESTYLE LIBRE CGM Study
This study is evaluating the safety and accuracy of the Freestyle Libre CGM when worn for 31 days. The goal is to improve diabetes care and technology for everyone who depends on it. Participating in this study will help advance diabetes technology and care, while receiving cutting-edge CGM devices at no cost. This study requires 7 clinic visits, including four 12-hour frequent sampling visits. Compensation is $3,325 for completion of study visits.
You may be eligible for this study if you:
- Are an adult (18+) who has been diagnosed with Type 1 or Type 2 diabetes
- Are currently using insulin therapy (must be a pump or at least 3 daily injections)
- Are willing to use a CGM device during the study period
Several Upcoming CGM Trials
Upcoming clinical trials are looking for volunteers to help evaluate new continuous glucose monitoring (CGM) technologies. Participants play an important role in improving tools that may support diabetes care in the future, with all studies conducted under strict safety and ethical oversight.
Find a Clinical Trial Near You!
If the above clinical trials and studies don’t work for you, you can utilize Breakthrough T1D and Antidote’s Clinical Trial Connection Tool to find one that resonates with you! To utilize this tool visit this link, or if you want to learn more about Clinical Trials in general, visit here.